News for PRTC Stock

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF) PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference PureTech Announces Annual Results for Year Ended December 31, 2024 PureTech Health: Notice of Results PureTech Appoints Peel Hunt as Joint UK Corporate Broker PureTech Health plc Statement Regarding Press Speculation PureTech to Present at the Leerink Partners Global Healthcare Conference PureTech Founded Entity Seaport Therapeutics Announces the Publication of New Research Demonstrating Increased Lymphatic Transport with up to 55 Percent Drug Absorption via Lymphatics with GlyphTM Platform PureTech Founded Vedanta Biosciences Publishes Additional Phase 2 VE303 Results in Nature Medicine PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML) PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference PureTech Appoints UBS as UK Corporate Broker PureTech’s Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024 PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors PureTech to Present at Two Upcoming Investor Conferences PureTech Founded Entity Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting PureTech to Present at CHEST 2024 Annual Meeting PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies PureTech Appoints Michele Holcomb, PhD, to Board of Directors PureTech Health: Notice of Half-Yearly Results PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial PureTech Health: Completion of Tender Offer & Total Voting Rights PureTech Health: Results of the Tender Offer PureTech Announces Change of Board Role PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team PureTech Health: Results of Annual General Meeting PureTech Health: Result of General Meeting PureTech Founded Entity Akili Interactive and Virtual Therapeutics Announce Entering Into Definitive Merger Agreement to Establish Leading Digital Health Company PureTech to Present at the Jefferies Global Healthcare Conference PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments PureTech Health: Notice of Results PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions PureTech Proposes $100 Million Capital Return Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia PureTech to Present at Two Upcoming Investor Conferences PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan PureTech to Present at 42nd Annual J.P. Morgan Healthcare Conference PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023 PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia PureTech Founded Entity Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers PureTech to Present at Two Upcoming Investor Conferences PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults at CHEST Annual Meeting PureTech Founded Entity Vedanta Biosciences Announces First Patient Dosed in Phase 2 Clinical Trial of VE202 for the Treatment of Ulcerative Colitis and Receives Fast Track Designation KarXT, invented at PureTech, submitted for FDA Approval in Schizophrenia PureTech Announces the Appointment of Robert Lyne as Chief Portfolio Officer PureTech Health: Notice of Half-Yearly Results PureTech Awarded up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-associated Tremor/Ataxia Syndrome PureTech Initiates Phase 2a Clinical Trial of LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders Results of PureTech's Annual General Meeting PureTech to Present at the Jefferies Healthcare Conference PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week PureTech Founded Entity Akili Announces Adults with ADHD See Significant Improvements in Attention, ADHD Symptoms, and Quality of Life in Clinical Trial of Akili’s EndeavorRx® Video Game-Based Therapeutic PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies PureTech Founded Entity Vedanta Biosciences Publishes Phase 2 Results in the Journal of the American Medical Association and Presents at ECCMID PureTech Health: Notice of Results PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million PureTech to Present at the Barclays Global Healthcare Conference PureTech Founded Entity Sonde Health and Massachusetts General Hospital Selected for National Institute on Aging Study to Examine Use of Voice in Remote Detection and Monitoring of Mild Cognitive Impairment Including Frontotemporal Disorders (FTD) PureTech to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression PureTech to Present at the SVB Securities Global Biopharma Conference Vedanta Biosciences to Present at Upcoming Investor Conferences PureTech’s LYT-300 (Oral Allopregnanolone) Demonstrates Oral Bioavailability, Tolerability and GABAA Receptor Target Engagement in Healthy Volunteers PureTech to Present at 41st Annual J.P. Morgan Healthcare Conference PureTech Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology (ASH) Annual Meeting PureTech Founded Entity Sonde Health Raises $19.25 Million Series B for Voice-Based Health Monitoring PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform PureTech to Present at Two Upcoming Investor Conferences PureTech to Present at the Jefferies London Healthcare Conference Vedanta Biosciences to Present at the 9th International Human Microbiome Consortium Congress PureTech to Present at the Credit Suisse 31st Annual Healthcare Conference PureTech to Present at the Morgan Stanley Global Healthcare Conference PureTech Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022 PureTech Founded Entity Sonde Health Announces Multi-Year Partnership with Koye Pharmaceuticals PureTech Health: Notice of Half-Yearly Results PureTech Founded Entity Akili Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan PureTech Founded Entity Akili Announces the Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of AKL-T01 Product Candidate PureTech Founded Entity Akili Announces Public Company Board of Director Nominees Vedanta Biosciences to Present at Upcoming Investor Conferences PureTech Initiates Late-Stage Clinical Study of Wholly-Owned Candidate LYT-100 (Deupirfenidone) in IPF and Advances LYT-200 (Anti-Galectin-9 mAb) PureTech Founded Entity Vedanta Biosciences Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia Vedanta Unveils State-of-the-Art Manufacturing Facility to Provide Clinical and Commercial Supply of Oral Therapies Based on Defined Bacterial Consortia Results of Annual General Meeting PureTech Meets Milestone of Achieving Oral Bioavailability of Allopregnanolone in Healthy Adults Dosed with LYT-300 PureTech Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute “Long” COVID with Respiratory Complications Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference PureTech Founded Entity Akili Announces Veteran Life Sciences Executive Matt Franklin in Newly Created Role of President and Chief Operating Officer PureTech to Present at the Jefferies Healthcare Conference PureTech Founded Entity Akili Integrates First-of-its-Kind Prescription Video Game Treatment with the Virtual World Through Partnership with Roblox PureTech Founded Entity Vedanta Biosciences Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting Vedanta Presents Data from Multiple Studies at Digestive Disease Week 2022 Annual Meeting PureTech to Present at the UBS Global Healthcare Conference PureTech Presents Additional Phase 1 Data for LYT-100 at American Thoracic Society 2022 PureTech Announces Share Buyback Program Update PureTech Announces Share Buyback Program of up to $50 Million PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022 PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study PureTech Announces Annual Results for Year Ended December 31, 2021 PureTech Founded Entity Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results Vedanta Biosciences Publishes Phase 1a/1b Results for Lead Program VE303 in Cell Host & Microbe and Highlights Planned Presentations of Phase 2 VE303 Results PureTech Founded Entity Akili Announces American Journal of Psychiatry Publication of Data Demonstrating its Digital Therapeutic AKL-T03 Improves Cognitive Impairments in Adults w/ Major Depressive Disorder When Combined w/ Antidepressant Medication PureTech Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine (a Clinically-Validated Opioid Replacement Therapy) PureTech Health: Notice of Results PureTech Appoints Sharon Barber-Lui to Board of Directors & Audit Committee PureTech Founded Entity Akili Appoints Game Industry Veteran Behind Bejeweled, Plants vs. Zombies as Chief Product Officer PureTech Founded Entity Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic PureTech Founded Entity Akili Named to Fast Company’s Annual List of the World’s 50 Most Innovative Companies for 2022 Vedanta Biosciences to Present at Chardan’s 2022 Metagenomics and Microbiome Medicines Summit PureTech Founded Entity Akili Announces PLOS ONE Publication of Clinical Study Results and EEG Data Showing Akili Digital Therapeutic EndeavorRx® Activates Systems in Brain Key to Attentional Functioning PureTech Founded Entity Akili Interactive Announces Filing of Registration Statement on S-4 in Connection with its Proposed Business Combination with Social Capital Suvretta Holdings Corp. I PureTech to Present at the SVB Leerink 11th Annual Global Healthcare Conference PureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting Norms Follica Announces Poster Presentation Demonstrating Unmet Treatment Needs in Androgenetic Alopecia at 2022 Winter Clinical Dermatology Conference and 2022 Maui Derm Meeting PureTech Founded Entity Gelesis, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of its Business Combination with Capstar PureTech to Present at 40th Annual J.P. Morgan Healthcare Conference PureTech’s LYT-100 (Deupirfenidone) Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone PureTech Provides End of Year Report on Key Progress Across Wholly Owned Programs and Founded Entities PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates PureTech Announces Participation in Two Upcoming Investor Conferences PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China PureTech Announces Participation at the Jefferies London Healthcare Conference PureTech Is Pleased to Note Publication in Nature’s Scientific Reports Featuring the Gelesis Foundational Biomimetic Platform for Treating Obesity and Conditions Related to Diet-Induced Gut Damage PureTech Founded Entity Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary Vedanta Biosciences Appoints Simona Levi as Chief Legal Officer and Corporate Secretary PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA PureTech Founded Entity Akili Announces Topline Results from Shionogi Phase 2 Study in Japan PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia PureTech Health plc – Half-Year Report PureTech Presents Phase 1 Data for LYT-100 at the European Respiratory Society International Congress 2021 PureTech Founded Entity Akili Enters Strategic Licensing Agreement with TALi, Extending Akili Portfolio and Industry Leadership in Prescription Digital Therapeutics for Cognitive Impairments PureTech Announces the Appointment Julie Krop, M.D., as Chief Medical Officer PureTech Announces That Imbrium Therapeutics Has Exercised License Option to LYT-503/IMB-150 for Interstitial Cystitis/Bladder Pain Syndrome PureTech: Notice of Half-Yearly Results PureTech Founded Entity Akili Releases New Gameplay Features in the First and Only FDA-Cleared Video Game Treatment for Children With ADHD PureTech Founded Entity Vedanta Biosciences Completes $68 Million Series D Financing PureTech Founded Entity Gelesis, the Maker of Plenity®, to Become a Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp. PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined with a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML) PureTech Founded Entity Sonde Health Announces Collaboration with Qualcomm Technologies for Use of Vocal Biomarker Technology on Qualcomm Snapdragon Mobile Platforms PureTech Announces Clinical Trial and Supply Agreement with BeiGene to Evaluate LYT-200 and Tislelizumab in Patients with Difficult-to-Treat Solid Tumors PureTech Founded Entity Vedanta Biosciences Announces New Data from Phase 1 Study of VE202 for the Treatment of Inflammatory Bowel Disease Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC) PureTech Founded Entity Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy Elderly Volunteers PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics Results of Annual General Meeting PureTech Founded Entity Gelesis Presents Findings on Plenity®-Induced Weight Loss at the American Association of Clinical Endocrinology (AACE) 2021 Annual Virtual Meeting PureTech Founded Entity Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital Therapeutics PureTech to Present at the Jefferies Virtual Healthcare Conference PureTech Forms Clinical Advisory Board for Idiopathic Pulmonary Fibrosis and Related Lung Disorders PureTech Announces Nature Publication Supporting Modulation of Meningeal Lymphatics to Target Alzheimer’s Disease Pathologies PureTech Founded Entity Gelesis Appoints Procter & Gamble Veteran Jane Wildman to Board of Directors Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit PureTech Announces Annual Results for Year Ended December 31, 2020 PureTech Presents Promising Preclinical Data from LYT-210 Immuno-Oncology Program at American Association for Cancer Research (AACR) Annual Meeting PureTech to Present at Two Upcoming Investor Conferences PureTech Founded Entity Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Potential Treatment for Patients with COVID Brain Fog PureTech Founded Entity Akili Announces the Results of EndeavorRx™ Clinical Study in Pediatric ADHD Published in Nature Digital Medicine PureTech Announces Board Member Retirement PureTech: Notice of Results PureTech to Present at The Barclays Global Healthcare Conference PureTech Founded Entity Karuna Therapeutics Announces Pricing of Public Offering of Common Stock Vedanta Biosciences to Present at Upcoming Investor Conferences PureTech Announces Publication of Glyph™ Platform Preclinical Proof-of-Concept Study in Journal of Controlled Release PureTech Founded Entity Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia PureTech to Present at The SVB Leerink 10th Annual Global Healthcare Conference PureTech Receives Approximately $118 Million from Sale of Portion of Founded Entity Shares PureTech Founded Entity Vor Biopharma Closes Over $200M Initial Public Offering PureTech Founded Entity Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering PureTech Adds Bharatt Chowrira, PureTech’s President and Chief of Business and Strategy, to Board of Directors PureTech Founded Entity Vor Announces FDA Clearance of IND Application for VOR33 PureTech Founded Entity Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to its Board of Directors Follica Adds Two Leaders in Aesthetic Medicine and Dermatology to Its Board of Directors PureTech Founded Entity Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. PureTech Announces the Appointment of George Farmer, Ph.D., as Chief Financial Officer PureTech to Present at 38th Annual J.P. Morgan Healthcare Conference and Other Conferences PureTech Advances Wholly Owned Candidate LYT-200 into Phase 1 Trial for Potential Treatment of Metastatic Solid Tumors PureTech Initiates Phase 2a trial of LYT-100 (Deupirfenidone) in Lymphedema Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology PureTech Founded Entity Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology Follica Announces Pilot Study for Female Pattern Hair Loss Published in International Journal of Women’s Dermatology PureTech Initiates Phase 2 trial of LYT-100 (Deupirfenidone) in Long COVID Respiratory Complications and Related Sequelae PureTech to Host Virtual R&D Day for Investors on December 11, 2020 Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to Its Board of Directors PureTech Founded Entity Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors PureTech’s LYT-100 (Deupirfenidone) Demonstrates Tolerability and Pharmacokinetic Proof-of-Concept in Phase 1 Multiple Ascending Dose and Food Effect Study PureTech to Present at Three Upcoming Investor Conferences